Medicine & Life Sciences
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
100%
Imatinib Mesylate
92%
Allogeneic Cells
43%
Cytogenetics
42%
Stem Cell Transplantation
37%
Leukemia, Myeloid, Chronic Phase
37%
Transplants
30%
Protein-Tyrosine Kinases
29%
Survival
27%
Hematopoietic Stem Cell Transplantation
26%
Fetal Blood
26%
Graft vs Host Disease
26%
Transplantation
24%
Acute Myeloid Leukemia
20%
Tissue Donors
19%
Chimeric Antigen Receptors
18%
Unrelated Donors
18%
Progression-Free Survival
18%
Natural Killer Cells
17%
Recurrence
16%
Stem Cells
16%
Cell Transplantation
15%
Busulfan
14%
Dasatinib
14%
Cyclophosphamide
13%
BK Virus
12%
Leukemia
12%
fludarabine
12%
Therapeutics
12%
T-Lymphocytes
11%
Phosphotransferases
10%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10%
Philadelphia Chromosome
8%
Mortality
8%
GATA2 Deficiency
8%
Residual Neoplasm
8%
Cell- and Tissue-Based Therapy
8%
Homologous Transplantation
8%
Incidence
7%
KIR Receptors
7%
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
7%
Mutation
7%
Inotuzumab Ozogamicin
6%
Hematologic Neoplasms
6%
B-Lymphocytes
6%
Haploidentical Transplantation
6%
Rituximab
6%
Clofarabine
6%
Hematopoietic Stem Cells
6%
Comorbidity
5%